Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by Point72 Asset Management L.P.

Point72 Asset Management L.P. increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 43.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,935,924 shares of the biopharmaceutical company's stock after buying an additional 895,304 shares during the quarter. Point72 Asset Management L.P. owned about 1.87% of Ocular Therapeutix worth $25,073,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $53,000. Tower Research Capital LLC TRC grew its stake in shares of Ocular Therapeutix by 2,045.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 8,446 shares during the period. Walleye Capital LLC acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $90,000. Finally, XTX Topco Ltd acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $99,000. Institutional investors and hedge funds own 59.21% of the company's stock.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,475 shares of Ocular Therapeutix stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. The trade was a 0.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of Ocular Therapeutix stock in a transaction dated Thursday, May 8th. The shares were bought at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the acquisition, the director now owns 172,704 shares in the company, valued at approximately $1,202,019.84. This trade represents a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Stock Up 0.7%

OCUL stock opened at $7.22 on Friday. The firm has a 50-day simple moving average of $7.41 and a 200-day simple moving average of $8.15. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $1.15 billion, a P/E ratio of -5.47 and a beta of 1.51. Ocular Therapeutix, Inc. has a 52 week low of $4.79 and a 52 week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). The firm had revenue of $17.08 million during the quarter, compared to analysts' expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. Equities analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on OCUL shares. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $15.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. William Blair began coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating on the stock. Needham & Company LLC decreased their target price on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Finally, Royal Bank of Canada began coverage on Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 target price on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.